BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34756766)

  • 1. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy.
    Takashio S; Yamada T; Nishi M; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
    J Cardiol; 2022 Jan; 79(1):50-57. PubMed ID: 34756766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive detection and differentiation of cardiac amyloidosis using
    Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
    Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of quantitative
    Ogasawara K; Shiraishi S; Tsuda N; Sakamoto F; Oda S; Takashio S; Tsujita K; Hirai T
    Jpn J Radiol; 2022 May; 40(5):508-517. PubMed ID: 34973114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive
    Nishi M; Takashio S; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Kidoh M; Oda S; Gushima R; Matsushita K; Fukushima S; Ueda M; Tsujita K
    Circ J; 2022 Jun; 86(7):1113-1120. PubMed ID: 35599006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
    Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
    Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
    Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
    J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Gluteus Medius Muscle Biopsy to Confirm Amyloid Transthyretin Deposition in Wild-type Transthyretin Cardiac Amyloidosis: A Report of Two Cases.
    Takahashi K; Iwamura T; Hiratsuka Y; Sasaki D; Yamamura N; Ueda M; Morioka H; Yoshino M; Enomoto D; Uemura S; Okura T; Sakaue T; Ikeda S
    Intern Med; 2024 Jun; 63(11):1575-1584. PubMed ID: 37899242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.
    Gimelli A; Aimo A; Vergaro G; Genovesi D; Santonato V; Kusch A; Emdin M; Marzullo P
    Amyloid; 2020 Dec; 27(4):237-243. PubMed ID: 32441155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population.
    Bourque JM; Schepart A; Bhambri R; Castaño A; O'Brien A; Chen Y; Prasad S; Roy A; Grodin JL
    Am J Cardiol; 2022 Mar; 167():98-103. PubMed ID: 35022130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.
    González-López E; Gagliardi C; Dominguez F; Quarta CC; de Haro-Del Moral FJ; Milandri A; Salas C; Cinelli M; Cobo-Marcos M; Lorenzini M; Lara-Pezzi E; Foffi S; Alonso-Pulpon L; Rapezzi C; Garcia-Pavia P
    Eur Heart J; 2017 Jun; 38(24):1895-1904. PubMed ID: 28329248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Wlodarski R; Seibert K; Issa NP; O'Brien-Penney B; Soliven B; Sarswat N; Appelbaum D; Rezania K
    Muscle Nerve; 2023 Feb; 67(2):111-116. PubMed ID: 36222831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Wild-type Cardiac Transthyretin Amyloidosis Diagnosed by Non-invasive Methods.
    Lizarazo Ortega DA; Valderrama BP; González-Robledo G; Trujillo PB
    Curr Med Imaging; 2023; 19(4):402-406. PubMed ID: 35692154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.